NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
Phase 3
Completed
- Conditions
- DyslipidemiaHypertensionHypercholesterolemia
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 412
- Registration Number
- NCT00385931
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 21
- Registration Number
- NCT00380445
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇩🇪Novartis Investigative Site, Investigative Centers, Germany
A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00380380
- Locations
- 🇩🇪
Munich, 81377, Germany, Munich, Germany
Topical Diclofenac Gel in Patients With Superficial Inflammation of the Veins
Phase 4
Completed
- Conditions
- Superficial Thrombophlebitis of the Upper Limb
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2007-12-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00377806
- Locations
- 🇩🇪
Novartis, Nürnberg, Germany
Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 43
- Registration Number
- NCT00376259
- Locations
- 🇺🇸
Novartis, San Diego, California, United States
🇨🇳Novarits, Kaohsuing, Taiwan
Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions
Phase 3
Terminated
- Conditions
- Breast Cancer With Bone Metastasis
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00372710
A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
Phase 4
Completed
- Conditions
- Renal Transplantation
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 228
- Registration Number
- NCT00369161
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2007-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 370
- Registration Number
- NCT00368134
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 132
- Registration Number
- NCT00367939
Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 275
- Registration Number
- NCT00367978
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath